» Articles » PMID: 2011574

Molecular Basis of Galactosemia: Mutations and Polymorphisms in the Gene Encoding Human Galactose-1-phosphate Uridylyltransferase

Overview
Specialty Science
Date 1991 Apr 1
PMID 2011574
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

We describe the molecular characterization of two mutations responsible for galactosemia, an inherited disorder of galatose metabolism that causes jaundice, cataracts, and mental retardation in humans. The coding region of galactose-1-phosphate uridylyltransferase (GALT; UDPglucose:alpha-D-galactose-1-phosphate uridylyltransferase, EC 2.7.7.12) was amplified by the polymerase chain reaction from total cDNA of a classic galactosemic individual and was characterized by direct sequencing of the products. Two missense mutations were identified: (i) replacement of valine-44 by methionine and (ii) replacement of methionine-142 by lysine. These mutations led to a drastic reduction in GALT activity when individual mutant cDNAs were overexpressed in a mammalian cell system, although full-length protein is synthesized in this assay. The two galactosemia mutations account for 3 of the 15 galactosemia alleles analyzed. These results suggest that galactosemia is caused by a variety of mutations, which might be responsible for the observed clinical heterogeneity of this disorder. We also present the molecular characterization of two GALT polymorphisms: (i) replacement of leucine-62 by methionine and (ii) replacement of asparagine-314 by aspartate. It appears that galactosemia mutations tend to occur in regions that are highly conserved throughout evolution while the polymorphisms change variable residues.

Citing Articles

Early postnatal alterations in follicular stress response and survival in a mouse model of Classic Galactosemia.

Hagen-Lillevik S, Johnson J, Lai K J Ovarian Res. 2022; 15(1):122.

PMID: 36414970 PMC: 9682695. DOI: 10.1186/s13048-022-01049-2.


Classic galactosaemia in the Greek Cypriot population: An epidemiological and molecular study.

Papachristoforou R, Petrou P, Sawyer H, Williams M, Drousiotou A Ann Hum Genet. 2019; 83(5):291-298.

PMID: 30994193 PMC: 6766971. DOI: 10.1111/ahg.12318.


Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic Function.

Guo C, Li Y, Wang P, Li Y, Qiu C, Li M Front Microbiol. 2018; 9:2682.

PMID: 30483228 PMC: 6243132. DOI: 10.3389/fmicb.2018.02682.


Sweet and sour: an update on classic galactosemia.

Coelho A, Rubio-Gozalbo M, Vicente J, Rivera I J Inherit Metab Dis. 2017; 40(3):325-342.

PMID: 28281081 PMC: 5391384. DOI: 10.1007/s10545-017-0029-3.


Clinical profile and molecular characterization of Galactosemia in Brazil: identification of seven novel mutations.

Garcia D, Camelo Jr J, Molfetta G, Turcato M, Souza C, Porta G BMC Med Genet. 2016; 17(1):39.

PMID: 27176039 PMC: 4866286. DOI: 10.1186/s12881-016-0300-8.


References
1.
Sly W, Sekhon G, Kennett R, Bodmer W, Bodmer J . Permanent lymphoid lines from genetically marked lymphocytes: success with lymphocytes recovered from frozen storage. Tissue Antigens. 1976; 7(3):165-72. DOI: 10.1111/j.1399-0039.1976.tb01047.x. View

2.
Flach J, Reichardt J, Elsas 2nd L . Sequence of a cDNA encoding human galactose-1-phosphate uridyl transferase. Mol Biol Med. 1990; 7(4):365-9. View

3.
Levy H, Hammersen G . Newborn screening for galactosemia and other galactose metabolic defects. J Pediatr. 1978; 92(6):871-7. DOI: 10.1016/s0022-3476(78)80351-5. View

4.
Chirgwin J, Przybyla A, MacDonald R, Rutter W . Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979; 18(24):5294-9. DOI: 10.1021/bi00591a005. View

5.
GITZELMANN R, Steinmann B . Galactosemia: how does long-term treatment change the outcome?. Enzyme. 1984; 32(1):37-46. DOI: 10.1159/000469448. View